Company Analysis
Sign in

PTC Therapeutics, Inc. (PTCT)

Nasdaq: PTCT · Pharmaceutical Preparations · Warren, NJ · filing with the SEC since 2004
Full chart Alerts Compare
Grade6.3
◀ Past 6.9● Present 5.8▶ Future 6.4
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

187 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to PTC Therapeutics, Inc.’s names, not what it holds today.

Patents granted
187
186 utility, 1 reissue, 1976 to Dec 31, 2025
Granted in 2025
11
Against 5 in 2024 and 18 in 2023
Applications published
215
8 of them in 2025
Names they are printed under
4
its own name, a subsidiary
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals30
Organic fine chemistry26
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
PTC THERAPEUTICS, INC. its own name
US, as the owner printed on each patent
176 granted
84 published
PTC Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
115 published
PTC Therapeutics MP, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
16 published
PTC Therapeutics MP, Inc. a subsidiary
US, as the owner printed on each patent
11 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 30, 202512,509,434Optically resolved Trolox intermediate and method for producing sameOrganic fine chemistryPTC THERAPEUTICS, INC.
Nov 4, 202512,458,629Method for treating nonsense mutation mediated duchenne muscular dystrophy in pediatric patientsPharmaceuticalsPTC THERAPEUTICS, INC.
Aug 26, 202512,398,140Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomiaOrganic fine chemistryPTC THERAPEUTICS, INC.
Aug 12, 202512,384,797Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomiaOrganic fine chemistryPTC THERAPEUTICS, INC.
Aug 12, 202512,384,789Compounds for treating Huntington's diseaseOrganic fine chemistryPTC THERAPEUTICS, INC.
Jun 17, 202512,329,757Methods for increasing sepiapterin plasma exposurePharmaceuticalsPTC Therapeutics MP, Inc.
Jun 10, 202512,325,706Polymorphic form of sepiapterinPharmaceuticalsPTC Therapeutics MP, Inc.
Apr 22, 202512,281,0832-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereofOrganic fine chemistryPTC THERAPEUTICS, INC.
Apr 8, 202512,269,829Polymorphs of sepiapterin and salts thereofPharmaceuticalsPTC Therapeutics MP, Inc.
Mar 25, 202512,257,252Compositions and methods for increasing tetrahydrobiopterin plasma exposurePharmaceuticalsPTC Therapeutics MP, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 18, 20252025/0382305COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3PharmaceuticalsPTC Therapeutics, Inc.
Nov 20, 20252025/0353855HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASEOrganic fine chemistryPTC Therapeutics, Inc.
Jul 17, 20252025/0230164POLYMORPHS OF SEPIAPTERIN AND SALTS THEREOFPharmaceuticalsPTC Therapeutics MP, Inc.
Jun 19, 20252025/0195529COMPOSITIONS AND METHODS FOR INCREASING TETRAHYDROBIOPTERIN PLASMA EXPOSUREPharmaceuticalsPTC Therapeutics MP, Inc.
Jun 19, 20252025/0195526PHARMACEUTICAL COMPOSITIONS COMPRISING SEPIAPTERIN AND USES THEREOFPharmaceuticalsPTC Therapeutics MP, Inc.
Jun 12, 20252025/0186437CARBOLINE COMPOUNDS AND USE THEREOFPharmaceuticalsPTC Therapeutics, Inc.
Jun 5, 20252025/0179078INHIBITORS OF NLRP3PharmaceuticalsPTC Therapeutics, Inc.
Feb 6, 20252025/0041305PHARMACEUTICAL COMPOSITION OF SEPIAPTERINPharmaceuticalsPTC Therapeutics, Inc.
Dec 12, 20242024/0409928NOVEL RNA TRANSCRIPTPharmaceuticalsPTC Therapeutics, Inc.
Nov 28, 20242024/0390338METHODS FOR TREATING NEUROGENERATIVE DISEASESPharmaceuticalsPTC Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 21 · Organic fine chemistry 5 · Computer technology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton PTCT · research, not advice